Clinical Research Associate Practice
The Clinical Research Associate Practice domain tests whether you understand the CRA's defined role under ICH GCP and how it differs from the investigator's, the sponsor's, and the auditor's. Questions probe qualification and training requirements, what a monitor may and may not do, and how monitoring findings are documented and escalated.
The CRA's regulatory basis
ICH E6(R2) section 5.18 makes the sponsor responsible for selecting and training monitors. A monitor must have adequate medical, scientific, and clinical knowledge, know the protocol and investigational product, understand GCP and applicable regulations, and be documented as trained before monitoring. Section 5.18.4 lists the monitoring scope: verify investigator qualifications and resources, verify investigational product storage and accountability, verify that the protocol and amendments were followed, verify source data against CRFs, and check informed consent. 21 CFR 312.53 separately requires a signed Form FDA 1572 before any investigational drug is shipped.
Boundaries of the role
The CRA verifies and documents; the site performs. A monitor must not make clinical judgments, complete CRFs, correct source data, obtain consent, or instruct site staff to alter records. Findings are recorded in a monitoring report and a follow-up letter with dated action items.
Worked example
At a site initiation visit the CRA finds the sub-investigator has a CV but no documented GCP training, and the Form FDA 1572 is unsigned. Reasoning: without a signed 1572 the site is not eligible to receive investigational product (21 CFR 312.53), and undocumented GCP training is an unresolved qualification gap (ICH E6 4.1.2). Correct action: do not release drug, document the gap in the SIV report, notify the sponsor, and set a dated corrective action before activation. The trap answer is to "note it for the first monitoring visit" - activating without these items is a compliance failure.
Traps that cost marks
- Confusing monitoring with auditing: auditors are independent of the study team; monitors are part of it.
- Assuming 100% source data verification is required - E6(R2) expects a risk-based, documented approach.
- "Fixing" a CRF or source entry rather than documenting a query.
- Leaving verbal instructions undocumented, with no contact report or follow-up letter.
- Treating the CRA as responsible for site staffing or clinical decisions.